CACNA1G and Ataxia: Numerous studies have confirmed the engagement of VGCCs in age‐related disease, including Parkinson disease (Cav1.3) (Zamponi et al., 2015), ataxia (Cav2.1) (Dorgans et al., 2017), Alzheimer's disease (Cav3.1) (Rice et al., 2014).